Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Vieth

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Proceedings of the National Academy of Sciences of the United States of America|March 25, 2022
Structural determinants of dual incretin receptor agonism by tirzepatideBingfa Sun, Francis S Willard, Dan Feng, et al.
Journal of Medicinal Chemistry|April 2, 2005
Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacyAlfonso de Dios, Chuan Shih, Beatriz López de Uralde, et al.
Molecular Cancer Therapeutics|January 30, 2004
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridinesChafiq Hamdouchi, Heather Keyser, Elizabeth Collins, et al.
ACS Infectious Diseases|February 22, 2022
Identification of β-Lactams Active against <i>Mycobacterium tuberculosis</i> by a Consortium of Pharmaceutical Companies and Academic InstitutionsBen Gold, Jun Zhang, Landys Lopez Quezada, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Proceedings of the National Academy of Sciences of the United States of America|March 25, 2022
Structural determinants of dual incretin receptor agonism by tirzepatideBingfa Sun, Francis S Willard, Dan Feng, et al.
Journal of Medicinal Chemistry|April 2, 2005
Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacyAlfonso de Dios, Chuan Shih, Beatriz López de Uralde, et al.
Molecular Cancer Therapeutics|January 30, 2004
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridinesChafiq Hamdouchi, Heather Keyser, Elizabeth Collins, et al.
ACS Infectious Diseases|February 22, 2022
Identification of β-Lactams Active against <i>Mycobacterium tuberculosis</i> by a Consortium of Pharmaceutical Companies and Academic InstitutionsBen Gold, Jun Zhang, Landys Lopez Quezada, et al.
Pageof 4